Advertised cash-pay semaglutide pricing across tracked providers. Several figures are secondary and pending live re-verification; each is labeled.
Provider data may change · advertised price · last checked 2026-06-25 · availability may vary by state and prescribing basis.
| Provider | Advertised | Notes | Provenance |
|---|---|---|---|
| Mochi Health | ~$99 add-on | + ~$79 membership | secondary |
| Fifty 410 | ~$99–$199 | Dose-tiered (reported) | secondary |
| NexLife | $145–$165 | Flat; no membership (stated) | primary |
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.